220 related articles for article (PubMed ID: 11434729)
21. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion.
Rosen T; Doherty C
Dermatol Online J; 2007 Jul; 13(3):14. PubMed ID: 18328208
[TBL] [Abstract][Full Text] [Related]
22. Overnight response to infliximab in neurosarcoidosis: a case report and review of infliximab treatment practice.
Lorentzen AO; Sveberg L; Midtvedt Ø; Kerty E; Heuser K
Clin Neuropharmacol; 2014; 37(5):142-8. PubMed ID: 25229171
[TBL] [Abstract][Full Text] [Related]
23. Anti-TNF therapeutics for the treatment of sarcoidosis.
Crommelin HA; Vorselaars AD; van Moorsel CH; Korenromp IH; Deneer VH; Grutters JC
Immunotherapy; 2014; 6(10):1127-43. PubMed ID: 25428650
[TBL] [Abstract][Full Text] [Related]
24. Refractory chronic cutaneous sarcoidosis responsive to dose escalation of TNF-alpha antagonists.
Thielen AM; Barde C; Saurat JH; Laffitte E
Dermatology; 2009; 219(1):59-62. PubMed ID: 19468200
[TBL] [Abstract][Full Text] [Related]
25. [Pulmonary and renal involvement in a TNFα antagonist drug-induced sarcoidosis].
Olivier A; Gilson B; Lafontaine S; Pautot JX; Bindi P
Rev Med Interne; 2012 May; 33(5):e25-7. PubMed ID: 21592629
[TBL] [Abstract][Full Text] [Related]
26. Infliximab therapy for complicated sarcoidosis.
Cook MC
Ann Intern Med; 2002 Aug; 137(4):296-7; author reply 296-7. PubMed ID: 12186527
[No Abstract] [Full Text] [Related]
27. Sarcoidosis occuring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: report of two cases.
Toussirot E; Pertuiset E; Kantelip B; Wendling D
Clin Exp Rheumatol; 2008; 26(3):471-5. PubMed ID: 18578973
[TBL] [Abstract][Full Text] [Related]
28. Refractory retinal vasculitis due to sarcoidosis successfully treated with infliximab.
Cruz BA; Reis DD; Araujo CA;
Rheumatol Int; 2007 Oct; 27(12):1181-3. PubMed ID: 17520259
[TBL] [Abstract][Full Text] [Related]
29. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients.
Pritchard C; Nadarajah K
Ann Rheum Dis; 2004 Mar; 63(3):318-20. PubMed ID: 14962969
[TBL] [Abstract][Full Text] [Related]
30. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.
Finckh A; Simard JF; Gabay C; Guerne PA;
Ann Rheum Dis; 2006 Jun; 65(6):746-52. PubMed ID: 16339288
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of TNF antagonists in sarcoidosis: data from the Spanish registry of biologics BIOBADASER and a systematic review.
Maneiro JR; Salgado E; Gomez-Reino JJ; Carmona L;
Semin Arthritis Rheum; 2012 Aug; 42(1):89-103. PubMed ID: 22387045
[TBL] [Abstract][Full Text] [Related]
32. Infliximab treatment of sarcoidosis.
Serio RN
Ann Pharmacother; 2003 Apr; 37(4):577-81. PubMed ID: 12659618
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D
JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695
[TBL] [Abstract][Full Text] [Related]
34. Hypercalcemia from sarcoidosis successfully treated with infliximab.
Huffstutter JG; Huffstutter JE
Sarcoidosis Vasc Diffuse Lung Dis; 2012 Mar; 29(1):51-2. PubMed ID: 23311123
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor necrosis factor therapy in patients with difficult-to-treat lupus nephritis: a prospective series of nine patients.
Matsumura R; Umemiya K; Sugiyama T; Sueishi M; Umibe T; Ichikawa K; Yoshimura M;
Clin Exp Rheumatol; 2009; 27(3):416-21. PubMed ID: 19604433
[TBL] [Abstract][Full Text] [Related]
36. Tumor necrosis factor-alpha antagonist-induced sarcoidosis.
Clementine RR; Lyman J; Zakem J; Mallepalli J; Lindsey S; Quinet R
J Clin Rheumatol; 2010 Sep; 16(6):274-9. PubMed ID: 20808167
[TBL] [Abstract][Full Text] [Related]
37. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients.
Riancho-Zarrabeitia L; Calvo-Río V; Blanco R; Mesquida M; Adan AM; Herreras JM; Aparicio Á; Peiteado-Lopez D; Cordero-Coma M; García Serrano JL; Ortego-Centeno N; Maíz O; Blanco A; Sánchez-Bursón J; González-Suárez S; Fonollosa A; Santos-Gómez M; González-Vela C; Loricera J; Pina T; González-Gay MA
Semin Arthritis Rheum; 2015 Dec; 45(3):361-8. PubMed ID: 26092330
[TBL] [Abstract][Full Text] [Related]
38. TNF-α: a treatment target or cause of sarcoidosis?
Amber KT; Bloom R; Mrowietz U; Hertl M
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2104-11. PubMed ID: 26419478
[TBL] [Abstract][Full Text] [Related]
39. The CD4+ lymphopenic sarcoidosis phenotype is highly responsive to anti-tumor necrosis factor-{alpha} therapy.
Crouser ED; Lozanski G; Fox CC; Hauswirth DW; Raveendran R; Julian MW
Chest; 2010 Jun; 137(6):1432-5. PubMed ID: 20525654
[TBL] [Abstract][Full Text] [Related]
40. Relapse of severe sarcoidosis with an uncommon peritoneal location after TNFalpha blockade. Efficacy of rituximab, report of a single case.
Dasilva V; Breuil V; Chevallier P; Euller-Ziegler L
Joint Bone Spine; 2010 Jan; 77(1):82-3. PubMed ID: 20022779
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
